Reflow Medical

Name: Reflow Medical
Address: 208 Avenida Fabricante, Ste. 100, San Clemente, CA, 92672, US
Telephone: +19494810399

Reflow Medical, Inc. designs and develops technology used to treat cardiovascular disease.

09/01/2026

Great news for patient access to innovative BTK therapy in the United States.

We’re proud to share that CMS has approved a New Technology Add-on Payment (NTAP) for the FDA Breakthrough Device-designated Spur® Peripheral Retrievable Stent System, effective for discharges on or after October 1, 2026.

By recognizing the added costs of qualifying new technologies, NTAP may help hospitals address financial barriers to adoption and support timely access to Spur for Medicare beneficiaries.

For patients with infrapopliteal arterial disease, Spur provides temporary mechanical scaffolding and controlled lesion pe*******on as an adjunct to PTA. Following treatment, Spur is fully retrieved, leaving no permanent implant behind.

For more information on NTAP eligibility, coding, and payment:
https://www.reflowmedical.com/reimbursement/

Explore the revolutionary Spur® and review Important Safety Information:
https://www.reflowmedical.com/spur/

08/31/2026

Join the Great Circulation Challenge this September

In recognition of PAD Awareness Month, we're proud to support The Great Circulation Challenge, organized by the Global PAD Association, bringing people together through movement to raise awareness of Peripheral Artery Disease and vascular health.

Register for the challenge here: https://padwalk.org/register.html

Download the app.
Join the challenge.
Track your steps.
Help raise awareness for PAD.

From September 1 through 30, every contribution counts toward a collective goal of 60,000 miles, reflecting the approximately 60,000 miles of blood vessels in the human circulatory system.

Every walk, every mile and every participant helps bring greater visibility to
PAD and the importance of vascular health.

08/26/2026

Complex PCI can present different navigation and crossing challenges, requiring different catheter characteristics.

Cora Flex® combines a low profile with exceptional trackability and pushability to reach and cross the tightest lesions.

Cora Force® provides maximum tip force support for engaging heavily calcified and fibrotic lesions.

Both Cora Flex and Cora Force integrate our proprietary Cora Tech™ technology, which sets a new standard for coronary torqueable microcatheters.

Cora Tech enables highest bi-directional spinning freedom and best torque transmission compared to market leaders during navigation and crossing of complex coronary lesions.*

Two coronary torqueable microcatheters. Different designs for different lesion challenges. The same exceptional spinning freedom.

Learn more about Reflow Medical’s Cora Flex and Cora Force Torqueable Microcatheters:
https://www.reflowmedical.com/coracatheters/

For a complete listing of the Indications, Contraindications, Warnings, Precautions, Adverse Events, and Procedural Steps, please refer to the applicable Instructions for Use:
https://www.reflowmedical.com/resources/

08/24/2026

Long-Term Evidence for Spur® + PTX DCB in BTK Disease

Four-year outcomes from the DEEPER OUS study provide long-term insight into the durability of Spur® Retrievable Scaffold Therapy in conjunction with a paclitaxel-coated DCB in infrapopliteal lesions.

At 48 months:

96.6% freedom from major amputation
with no further major amputations observed between 36 and 48 months

84.5% freedom from CD-TLR
with no new CD-TLR cases after 24 months

Earlier outcomes further demonstrated 74.4% primary patency at 12 months
and a substantial reduction in patients with CLTI from 79.5% at baseline to 29.7% at 12 months, reflecting a clinically meaningful shift toward lower disease severity.

Together, these findings support the long-term durability of Spur® + PTX DCB, delivering strong long-term outcomes while leaving nothing behind.

Learn more about the 4-year DEEPER OUS data:
https://www.reflowmedical.com/wp-content/uploads/2026/08/DEEPER_OUS_Spur_PTX_DCB_MM0201_EU_Rev_A.pdf

For a complete listing of the Indications, Contraindications, Warnings, Precautions, Complications, and Directions for Use, please refer to the applicable U.S. and CE Instructions for Use (IFU):
https://www.reflowmedical.com/resources/

08/18/2026

CIRSE 2026 is coming up, and we’re excited to be part of it.
From scientific exchange to practical peer-to-peer insights, we’re looking forward to contributing across several touchpoints in Copenhagen:
• Scientific presentations on Retrievable Scaffold Therapy with Spur® in infrapopliteal disease
• Peer-to-peer insight sharing featuring the Spur® System, Wingman™ CTO Crossing Catheter, and Spex® / Spex LP Shapeable Support Microcatheter

Visit us at Booth D50 to meet the Reflow Medical team and learn more about our endovascular portfolio for complex lesion treatment.

Follow us for more details on presentations, sessions, and speakers.

See you in Copenhagen, September 5–9.

08/14/2026

In this case, Spur was successfully used in combination with drug-coated balloon (DCB) therapy as part of the treatment strategy for a patient with CLTI.

This first case marks an important milestone for endovascular therapy in Brazil and reflects the team’s commitment to advancing evidence-based treatment strategies for patients with complex peripheral arterial disease.

Thank you to Dr. Rodrigo Marcondes and the team for sharing their first experience with Spur, and to our local partner Eurogreen for their collaboration and on-site support.
Learn more about Spur:

https://www.reflowmedical.com/spur-ous/

08/11/2026

To everyone we connected with, exchanged ideas with, learned from, and simply spent time with at AMP 2026, thank you. We always appreciate the time together, and we’re grateful and proud that Retrievable Scaffold Therapy with the Spur® System is part of the conversation around CLTI treatment.

A special thank you to Dr. Jay Mathews and Dr. Marianne Brodmann for sharing new findings from the DEEPER clinical program, including sustained 12-month outcomes from the DEEPER REVEAL Trial¹ and late-breaking data showing sustained 4-year results from the DEEPER OUS Trial².

We’d also like to recognize Dr. Anahita Dua for presenting on Spur® from the main podium. Thank you for contributing to the important discussions around CLTI care and treatment strategies.

We’re grateful to be part of a meeting and a community so deeply committed to advancing amputation prevention. We look forward to seeing you again soon.

¹ DEEPER REVEAL investigating Spur following predilatation in subjects with below-the-knee chronic limb-threatening ischemia. Data on file for DEEPER REVEAL clinical trial (NCT05358353).
² DEEPER OUS investigating Spur in conjunction with a drug-coated balloon (DCB) in infrapopliteal artery disease. Data on file for DEEPER OUS clinical trial (NCT03807531).

For complete listing of the Indications, Contraindications, Warnings, Precautions, Complications, and Directions for Use, please refer to the applicable U.S. and CE Instructions for Use (IFU):
https://www.reflowmedical.com/resources/

08/06/2026

A big thank you to everyone who joined Reflow Medical at the Coronary CTO Device Workshop during Interventional Complications 2026.

Over three days in Seattle, we had the opportunity to connect with clinicians from across the field and showcase the new Cora Flex® and Cora Force® Torqueable Microcatheters through hands-on demonstrations.

We are grateful for the thoughtful conversations, valuable feedback, and shared commitment to advancing treatment options for complex coronary cases.

Thank you for making the workshop a success. We look forward to staying connected and seeing many of you again at future educational events and meetings.

08/05/2026

Earlier this year, we shared 12-month DEEPER REVEAL results, strengthening the evidence for the Spur® Peripheral Retrievable Stent System in patients with chronic limb-threatening ischemia (CLTI) and long, calcified below-the-knee (BTK) lesions.

As highlighted by Jay Mathews, MD, Principal Investigator of the DEEPER REVEAL study:
"DEEPER REVEAL findings compare favorably to historical PTA data, underscoring the role of Retrievable Scaffold Therapy in addressing key limitations in BTK interventions."

Key outcomes at 12 months included:

• Primary patency: 78.0%*
• Freedom from clinically driven TLR: 83.1%*
• Complete paired wound healing: 84.3%
• Rutherford class improvement: 80.0%

These findings support the role of Retrievable Scaffold Therapy (RST) in overcoming limitations associated with conventional BTK treatment approaches while delivering durable outcomes through a leave-nothing-behind strategy.

🔗 Read the full press release:
https://www.reflowmedical.com/reflow-medical-announces-12-month-results-from-deeper-reveal-trial-sustained-outcomes-with-the-spur-stent-system-in-clti/
🔗 Full U.S. Indications for Use:
https://www.reflowmedical.com/resources/

*At 12 months, vessel-related outcomes in appropriately selected vessels (core lab-measured reference vessel diameter ≥2.5 mm, per study protocol and indication for use) and patient-centered outcomes were assessed.

08/04/2026

Join us at AMP 2026!
See you in Boston from August 5-7. Visit Booth 301 to connect with our team and explore our portfolio for the treatment of complex vascular lesions, including the Spur Retrievable Stent System, Wingman™ CTO Crossing Catheter, and other innovative technologies.

Don't miss these DEEPER study presentations:
🔹 Jay Mathews, MD, will present an in-depth analysis of the 12-month DEEPER REVEAL data, evaluating the Spur System in patients with below-the-knee (BTK) chronic limb-threatening ischemia (CLTI).

🔹 Marianne Brodmann, MD, will present the first-ever 4-year DEEPER OUS outcomes, evaluating Retrievable Scaffold Therapy (RST) with the Spur System in combination with a drug-coated balloon (DCB).

We look forward to sharing the latest clinical evidence and connecting with you on site!

Address

208 Avenida Fabricante, Ste. 100
San Clemente, CA
92672

Telephone

+19494810399

Website

http://www.reflowmedical.com/

Alerts

Be the first to know and let us send you an email when Reflow Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Reflow Medical:

Want your business to be the top-listed Engineering Company in San Clemente?